Gender and lung cancer.

Although lung cancer is the leading cause of cancer death among men and women in the United States, female smokers appear to be at increased risk. After controlling for the number of cigarettes smoked, female sex imparts a significant, independent risk for most histologic types of lung cancer. Cigarette smoking, genetics, and endocrine factors may interact to contribute to the disparity in lung cancer risk between the sexes. Estrogens have direct and indirect actions in the lung, and estrogen has been implicated in lung carcinogenesis in female smokers. This review of the literature will focus on endocrine factors and tobacco carcinogens as risk factors for lung cancer in women.     

Immunotherapy in lung cancer.

More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in view of recent improved technologies and greater understanding of the underlying biology. In this review we discuss mechanisms of tumour immunotherapy, non-specific, specific and adoptive, with particular reference to a direct therapeutic action on all subtypes of lung cancer.     

Histamine and lung cancer. II. Human lung cancer cell line and histamine

Using tissue culture and biochemical technique, the effects of autacoid-histamine and histamine H-2 receptor's antagonist-cimetidine on human lung cancer cell line were studied. It was shown that histamine at the concentration of 1.8 x 10(-7) M stimulated proliferation of the lung cancer cells, but histamine at the concentration of 1.8 x 10(-4) M or cimetidine at 1.76 x 10(-7) M inhibited growth of the lung cancer cells. Relation between histamine, histidine decarboxylase, histamine formation capacity and tumor proliferation is discussed.     

The biology of lung cancer.

The incidence of lung cancer continues to rise worldwide with major increases in incidence observed in Third World countries. Unfortunately, the overall survival of patients with this disease has remained unchanged in the past 2 decades. In spite of this, there have been major advances in understanding the biologic properties of both small cell and non-small cell lung cancer, including the definition of specific autocrine growth factors, molecular advances associated with the pathogenesis of this disease, and determinants of the mechanism of drug resistance. Here we review the most recently recognized important biologic properties of lung cancer cells in vitro and in vivo and discuss the clinical relevance of application of these biologic properties in the management of patients with this disease.     

Multi-step evolution of lung cancer.

In an attempt to improve the poor survival rates for lung cancer, therapeutic strategies require a deeper understanding of the biological events contributing to the formation and progression of the disease. In particular, the importance of studying the different stages of lung cancer including early pre-neoplasia is being recognised and studies examining genetic changes in pre-invasive and invasive lesions are being used to identify key events in tumorigenesis.     

Imaging of recurrent lung cancer.

Local, regional and distant tumor recurrence is common following surgical resection for non-small cell lung cancer. It is important to be familiar with the patterns of recurrence and to differentiate them from the normal post-operative appearance and post-radiation changes. The risks and types of recurrence are influenced by various factors including preoperative tumor stage, histological type and type of surgical resection. Treated patients are at risk for developing a second lung primary, reported to be 1-4% per year, and therefore follow-up must be aimed at detecting not only recurrent cancer, but also a new, primary lung cancer. Different follow-up imaging strategies have been suggested, including conventional radiography, CT and/or PET scanning.     

Penile metastasis from lung cancer.

A case of metastatic tumor of the penis from lung cancer is reported. The patient, who had received a right pneumonectomy 17 months previously for a squamous cell carcinoma of the lung, complained of urinary retention and painful erection of the penis. He underwent an emergency suprapubic cystostomy. Twenty days after the procedure, he died of disseminated lung carcinoma. The autopsy demonstrated massive metastasis to the penis from squamous cell carcinoma of the lung. Penile metastasis from lung cancer is a very rare condition and only 14 cases of this secondary carcinoma have been reported.     

Serum-mediated immunosuppression in lung cancer.

Immunosuppression in 45 patients with lung cancer was studied by examining delayed cutaneous hypersensitivity reactions to DNCB and by analyzing the effect of the patient's serum on the proliferative response of normal donor lymphocytes. Both diminution of DNCB reactivity and inhibition of the proliferative response of normal donor lymphocytes to mitogens were associated with the stage of the disease and the presence of unresected tumor. Suppressive sera were associated with poor prognosis. The suppressive effects of patients' sera on lymphocytes from a normal donor suggest that the immunosuppression seen in lung cancer may be mediated by serum factors. The significant association of clinically evident tumor with this serum-mediated immunosuppression further suggests that the tumor itself could account for the appearance of these factors in the host. The clinical implications of these findings may be useful for designing new clinical trials.     

Vitamin A and lung cancer.

Retrospective dietary and smoking data were gathered by interview of 292 white male patients with lung cancer and 801 control patients with nonrespiratory, nonneoplastic diseases at Roswell Park Memorial Institute, Buffalo, New York. A computed index of vitamin A intake was used to differentiate lung cancer patients from controls. Lung cancer patients had lower values than did controls. The reduced relative risk (RR) of lung cancer associated with vitamin A was most evident among men who smoked heavily. For them, a dose-response relationship increasing to an RR of 2.4 for low values of the index was observed. Frequency of daily milk drinking was lower among patients with lung cancer. Lower RR was found among the men who smoked heavily and frequently consumed carrots. These findings are consistent with evidence from animal studies on inhibition of tumor incidence by retinoids and with previous findings in prospective and retrospective epidemiologic studies.     

Preventing the lung cancer epidemic.

There are approximately 11 million new cases of cancer diagnosedworldwide each year [1] of which one in eight is a lung cancer.Over one million people die from lung cancer each year. In Europe,in 2004, there were approximately 3 million new cases of cancerand 1.7 million deaths from cancer [2]. Lung cancer was thecommonest incident form of cancer (375 000 new cases) and thecommonest cause of death from cancer (340 000 deaths).     

Gene therapy for lung cancer.

In the pre-clinical research into the development of gene therapy for cancer, different strategies have evolved and shown promising results in the laboratory. However, most of these strategies will need further refinement to obtain clinical success. This is partly due to the lack of suitable vector systems which specifically can deliver the therapeutic gene to the target cells, and ensure expression of the therapeutic gene. In this review we will give an introduction to different strategies used in cancer gene therapy for neoplasms of the lung, and focus on how to target gene delivery to disseminated lung cancer cells. Tumor specific gene expression can be accomplished at different levels. One way to accomplish targeted gene delivery is by coupling of receptor specific ligands to the vector. Specific gene delivery to cells expressing the target receptor will occur by receptor mediated endocytosis of the vector. Further restriction of gene expression to cancer cells can be accomplished by utilizing promoters predominantly active in tumors. When gene therapy is targeted at different levels, efficient gene delivery to disseminated cancer cells by systemic vector administration will be an attractive future prospect.     

Paraneoplastic syndromes in lung cancer.

Paraneoplastic syndromes are caused by factors produced by cancer cells that often act at a site distant from both the primary site and its metastases. These syndromes are estimated to occur in only 7% to 15% of patients with cancer and are diagnoses of exclusion. If the definition of paraneoplastic syndrome is broadened to include indirect effects of the tumor such as cachexia or the anemia of chronic disease, the incidence is much higher. Lung cancer, particularly small cell lung cancer, is the most common malignancy causing paraneoplastic syndromes. This review focuses on recently published literature on paraneoplastic syndromes associated with lung cancer, including humoral hypercalcemia of malignancy, autoimmune paraneoplastic neurologic syndromes, neuromuscular disorders, and cancer cachexia. It includes advances in both molecular biology and immunology, and in clinical investigation.     

Blood basophils in lung cancer.

Peripheral-blood basophils were counted, in thick smears, in samples from patients with primary bronchial carcinoma, from patients in the same wards and from normal individuals. The median counts for patients with other chest conditions (15.5/microliter) and bronchial-carcinoma patients free of tumour months to years after resection (16/microliter) did not differ from those for normal individuals (19/microliter), but tumour-bearers showed higher counts (median 33/microliter), 24/41 having counts above the highest count in normal individuals (29/microliter): P less than 0.002). The highest values were in patients with squamous bronchial carcinoma, apparently reflecting spontaneous challenge of an anti-tumour immune response. In those tested at the time of diagnosis, higher values in both lymphocyte and basophil counts were related to surgical resectability.